Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2025-12-25 @ 2:15 AM
NCT ID:
NCT03300960
Eligibility Criteria:
Inclusion Criteria:
* Age between 18-35 years (both included)
* Regular Menses (between 25-35 days)
* Absence of physical and psychic pathologies at the time of oocyte donation
* BMI: 18-28 kg(m2 at the time of oocyte donation.
* Other criteria to comply with:
i. With no relevant personal or family medical history ii. Signing of Informed Consent iii. From a medical point of view:
1. Healthy ovaries and uterus, with no organic pathology
2. Ovaries without polycystic aspect
3. Antral Follicle Count \> 12 in the sum of both ovaries
4. Normal Karyotype
5. Negative results in infectious illness screening (Hepatitis B Virus; Hepatitis C Virus, VIH Virus Syphilis)
6. Results within range of general analysis of hemogram, hemostasia y biochemistry.
Exclusion Criteria:
* Any systemic or metabolic disorder which contraindicate the use of Gonadotrophines
* Medical background of Trombophlebitis or thromboembolic phenomena or Arterial Hypertension
* Severe hepatic insufficiency, cardiovascular illness
* Suspicion or evidence of malignity of mamarian glands or other hormone dependant genital organs
* Known infection of Hepatitis B Virus; Hepatitis C Virus or VIH Virus
* Known hypersensitivity to PMA or its excipients
* Any reason or cause which excluede from the oocyte donation program
* Participation in another clinical trial in the two months prior to the inclusion on this study
Healthy Volunteers:
True
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
35 Years
Study:
NCT03300960
Study Brief:
Protocol Section:
NCT03300960